¹Ì¼¼ÀÜÁ¸Áúȯ(MRD) °Ë»ç ½ÃÀå : ±â¼úº°, ÀûÀÀº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Minimal Residual Disease Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2025-2033
»óǰÄÚµå : 1675376
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 138 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¹Ì¼¼ÀÜÁ¸Áúȯ(MRD) °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 23¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 55¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³â¿¡ 9.7%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î »ê¾÷ÀÇ ÇöÀúÇÑ ¼ºÀå, ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿, ±Þ¼ÓÇÑ ±â¼ú Áøº¸°¡ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù.

¹Ì¼¼ÀÜÁ¸Áúȯ(MRD) °Ë»ç´Â ¾Ï Ä¡·á ÈÄ È¯ÀÚÀÇ Ã¼³»¿¡ ³²¾ÆÀÖÀ» ¼ö ÀÖ´Â ¼Ò·®ÀÇ ¾Ï¼¼Æ÷¸¦ °ËÃâÇÏ°í ¸ð´ÏÅ͸µÇϱâ À§ÇØ »ç¿ëµÇ´Â ÀÇ·á °Ë»ç·Î, ¹éÇ÷º´, ¸²ÇÁÁ¾, ´Ù¹ß¼º°ñ¼öÁ¾, ÀϺΠ°íÇü¾Ï µî ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀ» °Ë»çÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. MRD °Ë»ç´Â ¼¼Æ÷ÃøÁ¤, ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR), Â÷¼¼´ë¿°±â¼­¿­ºÐ¼®(NGS) µî ¹Î°¨µµ°¡ ³ôÀº ¹æ¹ýÀ» »ç¿ëÇϸç, MRD °Ë»ç´Â ¾Ï ȯÀÚ¸¦ ¸ð´ÏÅ͸µÇϰí Àǻ簡 ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î Ä¡·á ¹æÄ§À» °áÁ¤Çϴµ¥ Áß¿äÇÑ ÀÇ·á °Ë»ç·Î, Áúº´ÀÇ Àç¹ßÀ» Á¶±â¿¡ ¹ß°ßÇϰí Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. Áúº´ Àç¹ßÀ» Á¶±â¿¡ ¹ß°ßÇϰí, Ä¡·á È¿°ú¸¦ º¸´Ù Á¤È®ÇÏ°Ô Æò°¡Çϰí, ȯÀÚ¸¦ ½Äº°ÇÏ¿© ¸ÂÃã Ä¡·á °èȹÀ» À¯µµÇϰí, ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÏ°í ¸ÂÃãÇü Ä¡·á °èȹÀ» °­È­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¹Ì¼¼ÀÜÁ¸Áúȯ(MRD) °Ë»ç ½ÃÀå µ¿Çâ :

MRD °Ë»ç´Â ÀÜÁ¸ ¾Ï¼¼Æ÷¸¦ °ËÃâÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ´Â °í°¨µµ ±â¼ú·Î, Áúº´ÀÇ Àç¹ßÀ» Á¶±â¿¡ ½Ã»çÇÏ°í ¸ÂÃãÇü Ä¡·á °èȹÀ» ¾È³»ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â MRD °Ë»ç´Â Àü ¼¼°è¿¡¼­ ¾Ï À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó Á¶Ç÷ Á¶Á÷ ¶Ç´Â ¸é¿ª°è ¼¼Æ÷¿¡¼­ ½ÃÀ۵Ǵ Ç÷¾×¾Ï¿¡¼­ MRD °Ë»ç°¡ Áø´Ü ¹× ¸ð´ÏÅ͸µ Åø·Î ³Î¸® äÅõǰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÇü Ä¡·á °èȹ ¹× ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÏ´Â °³ÀÎÈ­µÈ ÀÇ·á¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼±È£µµÀÇ º¯È­´Â ¶Ç ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î ÀΰøÁö´É(AI)À» MRD °Ë»ç¿¡ ÅëÇÕÇÏ¿© ÆÐÅÏ ½Äº°, Àç¹ß °¡´É¼º ¿¹Ãø, Áø´ÜÀÇ Á¤È®¼º°ú À¯È¿¼º Çâ»ó, ÀÓ»óÀǰ¡ ȯÀÚ Ä¡·á¿¡ ´ëÇØ ´õ ¸¹Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áö¿øÇÔÀ¸·Î½á ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¥¿Á½Ã¸®º¸ÇÙ»ê(DNA) ¶Ç´Â ¸®º¸ÇÙ»ê(RNA)ÀÇ ¿°±â¼­¿­À» °áÁ¤Çϰí Áúº´°ú °ü·ÃµÈ À¯ÀüÀÚ º¯À̸¦ ¿¬±¸Çϱâ À§ÇÑ NGS ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ã¼³»¿¡¼­ ¾ÏÀ» À¯¹ßÇÒ ¼ö ÀÖ´Â ¹ß¾Ï¹°ÁúÀÇ Á¸À縦 È®ÀÎÇÏ´Â °ÍÀÇ Á߿伺¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ºÀå¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î »ê¾÷ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå, ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿, MRD °Ë»ç ÇÁ·Î±×·¥ ºÐ¾ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µî ´Ù¸¥ ¿äÀε鵵 ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ ¹Ì¼¼ÀÜÁ¸Áúȯ(MRD) °Ë»ç ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : ±â¼úº°

Á¦7Àå ½ÃÀå ³»¿ª : ÀûÀÀº°

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦10Àå ÃËÁø¿äÀΡ¤¾ïÁ¦¿äÀΡ¤±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global minimal residual disease (MRD) testing market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.7% during 2025-2033. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.

Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.

Minimal Residual Disease (MRD) Testing Market Trends:

The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.

Key Market Segmentation:

Technology Insights:

Application Insights:

End User Insights:

Regional Insights:

Competitive Landscape:

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Minimal Residual Disease (MRD) Testing Market

6 Market Breakup by Technology

7 Market Breakup by Application

8 Market Breakup by End User

9 Market Breakup by Region

10 Drivers, Restraints, and Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â